Two products that get lumped together
Founders often file venture debt and revenue-based financing (RBF) under one heading: money that does not dilute the cap table. They are different instruments, aimed at different companies, with different ways of hurting you if the plan slips. Choosing between them is mostly a question of who you are today and when your next equity round is likely to close.
Non-dilutive capital is getting more attention as a category. A Causo report on H1 2026 non-dilutive funding, last reviewed on October 7, 2026, pulls together the figures most founders ask about. It cites PitchBook and NVCA data showing US venture debt reached $49.6 billion across 674 deals through the third quarter of 2025. It also cites PitchBook for a median late-stage venture debt deal of $10.8 million in the first quarter of 2026, and for AI startups absorbing more than a third of 2025 venture debt dollars.
Those numbers describe a market that is large but concentrated. Big checks go to companies that already have institutional investors behind them. That matters if you are deciding which product to chase.
Venture debt: priced for companies with a sponsor
Venture debt is a term loan, usually extended after an institutional equity round. The Causo guide quotes SVB as saying it is generally not available to seed-stage companies, and it relays Stifel's advice to draw within 60 days of an equity close. The lender is underwriting your investors as much as your revenue.
On price, the Causo report cites Stifel for typical pricing of SOFR plus 600 to 900 basis points, with warrant coverage of 0.10% to 0.25% of fully diluted equity for every $1 million drawn. A separate benchmark piece from Ful, a lender that publishes its own rate guides, puts bank-sourced venture debt at roughly Prime plus 1 to 4 points and fund-sourced venture debt at Prime plus 5 to 9 points. It adds that fund lenders ask for larger warrant coverage than banks, and that total debt tends to sit around 0.5 to 1 times annual recurring revenue. Treat those as directional, since the two sources use different bases and a lender's own blog is not a neutral price list.
The practical reading: bank lenders are cheaper but pickier, and fund lenders will go further down the quality curve in exchange for a higher coupon and more warrants. Neither is free. Warrants are small slices of equity, but they are equity, and loan covenants can bite in a bad quarter.
Revenue-based financing: faster, smaller, often pricier
RBF flips the structure. Instead of a fixed monthly payment, you remit a percentage of revenue until you have repaid a multiple of the advance. Causo describes typical deals as $50,000 to $5 million, with a repayment cap of 1.1 to 1.5 times, repayment of 4% to 9% of monthly revenue, and eligibility that starts around $20,000 in monthly recurring revenue with at least six months of revenue data. It puts effective APRs at 15% to 30%. Ful's range for the cap is 1.2 to 1.5 times, with repayment at 3% to 10% of monthly revenue.
The headline multiple understates the cost when revenue grows quickly, because the cap gets paid back sooner and the annualized rate rises. A $100,000 advance with a 1.3 times cap costs $30,000 whether it takes eighteen months or six. Run both scenarios before you compare it to a loan quoted as an interest rate.
The benefit is access. RBF does not need a lead investor, a board seat, or a recent priced round. For a company with steady recurring revenue and low gross-margin risk, that can be a sensible way to fund customer acquisition when the payback period is short and known.
The stress test most term sheets skip
The most useful line in the Causo guide is a planning rule: do not treat RBF and debt as primary capital, and model cash impact assuming your next round closes six months late. That is a cheap exercise with a clear output. Take your current plan, push the equity close out by two quarters, and see what the debt service does to your runway.
A few questions to answer on paper before you sign:
- Debt service against burn. Ful suggests keeping debt service under 25% of net burn. If a late round pushes you past that, you have a covenant and a liquidity problem at the same moment.
- Revenue concentration. Revenue-linked repayments fall when revenue falls, which is a feature. But if one customer is a third of revenue and leaves, the cap still stands and the time to repay stretches.
- Prepayment and fees. Origination fees of 1% to 3% and any prepayment penalty belong in the all-in cost, not the footnotes.
- What the lender can do on default. Read the acceleration and security terms. Know what collateral secures the loan.
Beyond the US playbook
The same pattern of lenders stepping in where equity is scarce shows up abroad. Khaleej Times reported on June 22, 2026, citing Stride Ventures' Global Private Debt Report 2026, that private debt in the Gulf Cooperation Council region rose to $4.1 billion in 2025, about 8.2 times the prior year, and overtook venture capital deployment of $3.3 billion for the first time. Fintech accounted for 95.5% of that debt, and a handful of very large deals, including a $2.4 billion facility for Tamara, drove the total. The lesson for founders elsewhere is limited: that is lending to companies with receivables to finance, not a generic startup loan market. But it shows how quickly credit can take share when the asset being lent against is predictable.
What to watch next
Three things will decide whether these products get cheaper or tighter for founders:
- The reference rate. Venture debt floats off SOFR or Prime, so every move in policy rates flows into your monthly payment.
- Concentration in AI. If lenders keep steering dollars to AI companies, the remaining pool for everyone else is smaller and more selective, which can show up as higher warrants or tighter covenants.
- Equity round timing. Debt is easiest to raise right after an equity close, which is also when you need it least. Planning the draw ahead of the next raise, rather than after a miss, keeps your options open.
The takeaway for a CFO is straightforward. Use venture debt as a bridge between rounds that you can already see, and RBF as a tool for financing growth you can measure. Price both on an all-in basis, test them against a late round, and keep the equity story intact. This is general information, not advice on any particular financing.